

# US Family Health Plan

## Prior Authorization Request Form for fedratinib (**Inrebic**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be **faxed** to **617-562-5296**

OR

The patient may attach the completed form to the prescription and **mail** it to:

**Attn: Pharmacy, 77 Warren St, Brighton, MA 02135**

QUESTIONS? **Call 1-877-880-7007**

**Step 1** Please complete patient and physician information (please print):

Patient Name: _____	Physician Name: _____
Address: _____	Address: _____
Sponsor ID #: _____	Phone #: _____
Date of Birth: _____	Secure Fax #: _____

**Step 2** Please complete the clinical assessment:

1. Is the patient <b>GREATER THAN</b> or <b>EQUAL TO</b> 18 years of age?	<input type="checkbox"/> Yes Proceed to question 2	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
2. Is the requested medication being prescribed by or in consultation with a hematologist/oncologist?	<input type="checkbox"/> Yes Proceed to question 3	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
3. Will Inrebic be used for intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No Proceed to question 4
4. Please provide the diagnosis.	_____ Proceed to question 5	
5. Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
6. Provider acknowledges that serious and fatal encephalopathy including Wernicke's encephalopathy has occurred in patients treated with Inrebic. If thiamine deficiency is expected or confirmed, Inrebic should be discontinued immediately and the patient should receive emergent parenteral thiamine?	<input type="checkbox"/> Yes Proceed to question 7	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
7. Does the patient have vitamin B1 deficiency?	<input type="checkbox"/> No <b>STOP</b> Coverage not approved	<input type="checkbox"/> Yes Proceed to question 8

Prior Authorization Request Form for  
fedratinib (**Inrebic**)

<p><b>8. Will the following labs be assessed prior to starting Inrebic and periodically while the patient is taking the requested medication: thiamine (Vitamin B1), CBC with platelets, serum creatinine and BUN, hepatic panel and amylase and lipase?</b></p>	<p><input type="checkbox"/> Yes Proceed to question <b>9</b></p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p><b>9. Will nutritional status will be assessed prior to starting Inrebic and periodically while the patient is taking the requested medication?</b></p>	<p><input type="checkbox"/> Yes Proceed to question <b>10</b></p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p><b>10. What is the patient's age/gender?</b></p>	<p><input type="checkbox"/> Male – proceed to question <b>14</b> <input type="checkbox"/> Female of reproductive age – proceed to question <b>11</b> <input type="checkbox"/> Female NOT of reproductive age – <b>Sign and date below</b></p>	
<p><b>11. Is the patient pregnant or actively trying to become pregnant?</b></p>	<p><input type="checkbox"/> Yes <b>STOP</b> Coverage not approved</p>	<p><input type="checkbox"/> No Proceed to question <b>12</b></p>
<p><b>12. Is the patient breast-feeding?</b></p>	<p><input type="checkbox"/> Yes Proceed to question <b>13</b></p>	<p><input type="checkbox"/> No Proceed to question <b>14</b></p>
<p><b>13. Will the patient refrain from breastfeeding during treatment and for 1 month after cessation of treatment?</b></p>	<p><input type="checkbox"/> Yes Proceed to question <b>14</b></p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p><b>14. Will the patient take effective contraception during treatment and for 1 month after discontinuation?</b></p>	<p><input type="checkbox"/> Yes <b>Sign and date below</b></p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>

**Step 3** I certify the above is true to the best of my knowledge. Please sign and date:

**3**

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

[19 February 2020]